导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.88% | 1320/4773 |
| 近一周 | -0.92% | 1395/5465 |
| 近一月 | -3.58% | 2651/5421 |
| 近一季 | -8.17% | 3145/5231 |
| 近半年 | -3.58% | 2514/4920 |
| 近一年 | 9.86% | 1154/4394 |
| 近两年 | 73.52% | 954/2954 |
| 近三年 | 41.04% | 737/2253 |
| 成立以来 | 96.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.74% 1192/4961 |
19.13% 1320/5312 |
- - |
- - |
| 2025 | 32.55% 1172/4813 |
2.23% 1432/3635 |
2.43% 1570/4076 |
24.55% 1448/4524 |
1.63% 1294/4813 |
| 2024 | 6.07% 1791/3463 |
-2.06% 1313/2808 |
-4.88% 1581/3014 |
14.95% 1867/3129 |
-0.95% 1552/3463 |
| 2023 | -5.56% 752/2656 |
7.55% 557/2280 |
-4.01% 1011/2385 |
-4.58% 1169/2515 |
-4.13% 882/2655 |
| 2022 | -17.32% 574/2207 |
-13.31% 731/1919 |
3.16% 1204/2016 |
-10.00% 334/2113 |
2.73% 850/2208 |
| 2021 | 17.60% 227/1822 |
-1.38% 483/1255 |
9.68% 535/1330 |
5.07% 294/1466 |
3.48% 426/1822 |
| 2020 | 24.39% 634/1250 |
-4.19% 343/1028 |
16.43% 439/1067 |
7.97% 750/1164 |
3.29% 925/1184 |
| 2019 | 25.96% 587/1092 |
30.41% 247/739 |
-9.55% 666/788 |
0.34% 527/850 |
6.43% 611/918 |
| 2018 | - - |
- - |
- - |
- - |
-12.20% 425/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 平安500ETF联接A VS. 长安沪深300非周期A(740101) |